<DOC>
	<DOCNO>NCT02733419</DOCNO>
	<brief_summary>This open-label , randomize multi-center study compare efficacy safety continue enfuvirtide ( Fuzeon ) plus ( + ) OB therapy versus OB alone participants HIV-1 infection . Participants receive initial 28 week induction treatment enfuvirtide + OB . After 28 week participant plasma viral load less equal ( &lt; /= ) 400 copies/milliliter ( mL ) Week 16 less ( &lt; ) 50 copies/mL Week 24 randomize ratio 1:1 receive either enfuvirtide + OB OB alone another 24 week ( Week 52 ) .</brief_summary>
	<brief_title>Efficacy , Safety Study Optimized Background Antiretroviral Regimen ( OB ) Combination With Enfuvirtide Treatment-Experienced Participants With Human Immunodeficiency Virus-1 ( HIV-1 ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>Participants HIV1 infection Female participant without risk pregnancy Participants previously treat drug 2 3 different antiretroviral class Participants currently highly active antiretroviral treatment ( HAART ) 4 week plasma viral load 1,000 300,000 copy HIV1 ribonucleic acid per milliliter ( RNA/mL ) Participants possibility potentially effective OB without enfuvirtide , consist 2 5 drug , least two active least two different antiretroviral class Cluster differentiation 4 ( CD4 ) cell count great ( &gt; ) 50 cells/cubic millimeter ( mm^3 ) screen Participants resistance mutation detect reverse transcriptase and/or protease gene Enfuvirtidenaive participant Women childbearing age use effective mechanical contraception Pregnant breastfeed woman Presence HIV2 coinfection Participants participate participate another clinical trial 30 day prior selection trial Participants previously treat enfuvirtide Presence active opportunistic infection within 1 month study entry Existence Grade 4 clinical laboratory abnormality Cirrhosis severe hepatic failure Uncontrolled diabetes require insulin Consumption alcohol and/or narcotic and/or substance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>